03:41 AM EDT, 03/24/2025 (MT Newswires) -- TransCode Therapeutics ( RNAZ ) said Sunday it has agreed to sell about 10.3 million shares of its common stock and warrants to purchase up to 10.3 million shares at a price of $0.98 per share and accompanying warrant for total expected gross proceeds of $10 million.

The warrants will be exercisable at a price of $0.86 per share.

Net proceeds will be used for product development activities, working capital and other general corporate purposes, the company said.

Closing of the offering is expected to occur Tuesday, subject to customary closing conditions.